MAP2K1 and melanoma: The resistance of our MEK1 Q56P melanoma model to both MEK and BRAF inhibitors confirms the prior discovery of BRAF inhibitor cross-resistance with stable expression of exogenous MEK1 Q56 and MEK1 P124 mutant alleles in A375 cells [18].